QUARTERLY REPORT

Q1 2020 — Quarterly report

Q1 2020PDF · 36 pages138 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
È 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020
or
‘ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM 	TO
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware 	41-1321939
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota 	55343
(Address of principal executive offices) 	(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. 	Yes È 	No ‘
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit such files). 	Yes È 	No ‘
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	È 	Accelerated filer ‘ 	Non-accelerated filer 	‘
Smaller reporting company 	‘ 	Emerging growth company ‘
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ‘
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). 	Yes ‘ 	No È
As of April 30, 2020, there were 948,379,502 shares of the registrant’s Common Stock, $.01 par value per share, issued
and outstanding.

-- 1 of 36 --



-- 2 of 36 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1
Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 . . . . . . . 	1
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2020
and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2
Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended
March 31, 2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3
Condensed Consolidated Statements of Changes in Equity for the Three Months Ended
March 31, 2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31,
2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5
Notes to the Condensed Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6
1. Basis of Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6
2. Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7
3. Fair Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	9
4. Medical Costs Payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10
5. Short-Term Borrowings and Long-Term Debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11
6. Commitments and Contingencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	12
7. Segment Financial Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . 	15
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	24
Item 4. 	Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	24
Part II. Other Information
Item 1. 	Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25
Item 1A. Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	25
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	26
Item 6. 	Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	27
Signatures 	. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	28

-- 3 of 36 --

[THIS PAGE INTENTIONALLY LEFT BLANK]

-- 4 of 36 --

PART I
ITEM 1. 	FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data) March 31,
2020 December 31,
2019
Assets
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 21,569 	$ 10,985
Short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,876 	3,260
Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14,613 	11,822
Other current receivables, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,275 	9,640
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,866 	3,076
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6,608 	3,851
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	58,807 	42,634
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	36,578 	37,209
Property, equipment and capitalized software, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,173 	8,704
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	65,302 	65,659
Other intangible assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,199 	10,349
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,008 	9,334
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$189,067 	$173,889
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 22,772 	$ 21,690
Accounts payable and accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	22,845 	19,005
Short-term borrowings and current maturities of long-term debt . . . . . . . . . . . . . . . 	15,828 	3,870
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,509 	2,622
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	14,652 	14,595
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	78,606 	61,782
Long-term debt, less current maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	35,779 	36,808
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,030 	2,993
Other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,048 	10,144
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	127,463 	111,727
Commitments and contingencies (Note 6)
Redeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,741 	1,726
Equity:
Preferred stock, $0.001 par value —10 shares authorized; no shares issued or
outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	—
Common stock, $0.01 par value — 3,000 shares authorized; 947 and 948 issued
and outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10 	9
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	7
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	62,327 	61,178
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(5,360) 	(3,578)
Nonredeemable noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,886 	2,820
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	59,863 	60,436
Total liabilities, redeemable noncontrolling interests and equity . . . . . . . . . . . . . . . . 	$189,067 	$173,889
See Notes to the Condensed Consolidated Financial Statements
1

-- 5 of 36 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
March 31,
(in millions, except per share data) 	2020 	2019
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$50,640 	$47,513
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,431 	8,072
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,985 	4,318
Investment and other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	365 	405
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	64,421 	60,308
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	41,000 	38,939
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,015 	8,517
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,687 	7,381
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	723 	639
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	59,425 	55,476
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,996 	4,832
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(437) 	(400)
Earnings before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,559 	4,432
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,094) 	(875)
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,465 	3,557
Earnings attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(83) 	(90)
Net earnings attributable to UnitedHealth Group common shareholders . . . . . . . . . . . . 	$ 3,382 	$ 3,467
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3.56 	$ 	3.62
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3.52 	$ 	3.56
Basic weighted-average number of common shares outstanding . . . . . . . . . . . . . . . . . . . . 	949 	958
Dilutive effect of common share equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	13 	17
Diluted weighted-average number of common shares outstanding . . . . . . . . . . . . . . . . . . 	962 	975
Anti-dilutive shares excluded from the calculation of dilutive effect of common share
equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10 	8
See Notes to the Condensed Consolidated Financial Statements
2

-- 6 of 36 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
March 31,
(in millions) 	2020 	2019
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 3,465 	$3,557
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period . . . . . . . 	(349) 	520
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	80 	(119)
Total unrealized (losses) gains, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(269) 	401
Gross reclassification adjustment for net realized (gains) losses included in net
earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(18) 	4
Income tax effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4 	(1)
Total reclassification adjustment, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(14) 	3
Total foreign currency translation losses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,499) 	(2)
Other comprehensive (loss) income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,782) 	402
Comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,683 	3,959
Comprehensive income attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . 	(83) 	(90)
Comprehensive income attributable to UnitedHealth Group common shareholders . . . 	$ 1,600 	$3,869
See Notes to the Condensed Consolidated Financial Statements
3

-- 7 of 36 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Accumulated Other Comprehensive
Income (Loss)
Common Stock Additional
Paid-In
Capital Retained
Earnings
Net Unrealized Gains
(Losses) on
Investments
Foreign
Currency
Translation
Losses
Nonredeemable
Noncontrolling
Interests Total
Equity	Shares Amount
Balance at January 1, 2020 . . . . . . 	948 $ 	9 $ 	7 $ 	61,178 $ 	589 $ 	(4,167) $ 	2,820 $60,436
Adjustment to adopt ASU
2016-13 . . . . . . . . . . . . . . . . . . . 	(28) 	(28)
Net earnings . . . . . . . . . . . . . . . . . 	3,382 	59 	3,441
Other comprehensive (loss)
income . . . . . . . . . . . . . . . . . . . 	(283) 	(1,499) 	(1,782)
Issuances of common stock, and
related tax effects . . . . . . . . . . . 	5 	1 	320 	321
Share-based compensation . . . . . . 	234 	234
Common share repurchases . . . . . 	(6) 	— 	(510) 	(1,181) 	(1,691)
Cash dividends paid on common
shares ($1.08 per share) . . . . . . 	(1,024) 	(1,024)
Redeemable noncontrolling
interests fair value and other
adjustments . . . . . . . . . . . . . . . . 	(51) 	(51)
Acquisition and other adjustments
of nonredeemable
noncontrolling interests . . . . . . 	50 	50
Distribution to nonredeemable
noncontrolling interests . . . . . . 	(43) 	(43)
Balance at March 31, 2020 . . . . . . 	947 $ 	10 $ 	— $ 	62,327 $ 	306 $ 	(5,666) $ 	2,886 $59,863
Balance at January 1, 2019 . . . . . . 	960 $ 	10 $ 	— $ 	55,846 $ 	(264)$ 	(3,896) $ 	2,623 $54,319
Adjustment to adopt ASU
2016-02 . . . . . . . . . . . . . . . . . . . 	(13) 	(5) 	(18)
Net earnings . . . . . . . . . . . . . . . . . 	3,467 	60 	3,527
Other comprehensive income
(loss) . . . . . . . . . . . . . . . . . . . . . 	404 	(2) 	402
Issuances of common stock, and
related tax effects . . . . . . . . . . . 	5 	— 	56 	56
Share-based compensation . . . . . . 	239 	239
Common share repurchases . . . . . 	(12) 	— 	(34) 	(2,968) 	(3,002)
Cash dividends paid on common
shares ($0.90 per share) . . . . . . 	(860) 	(860)
Redeemable noncontrolling
interests fair value and other
adjustments . . . . . . . . . . . . . . . . 	(152) 	(152)
Acquisition and other adjustments
of nonredeemable
noncontrolling interests . . . . . . 	(109) 	132 	23
Distribution to nonredeemable
noncontrolling interests . . . . . . 	(83) 	(83)
Balance at March 31, 2019 . . . . . . 	953 $ 	10 $ 	— $ 	55,472 $ 	140 $ 	(3,898) $ 	2,727 $54,451
See Notes to the Condensed Consolidated Financial Statements
4

-- 8 of 36 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended
March 31,
(in millions) 	2020 	2019
Operating activities
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 3,465 	$ 3,557
Noncash items:
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	723 	639
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	202 	134
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	231 	243
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	45 	42
Net change in other operating items, net of effects from acquisitions and changes in AARP
balances:
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(2,652) 	(1,421)
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,249) 	(1,495)
Medical costs payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,120 	1,125
Accounts payable and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,137 	318
Unearned revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(79) 	92
Cash flows from operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,943 	3,234
Investing activities
Purchases of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(3,866) 	(3,540)
Sales of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,170 	1,510
Maturities of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,726 	1,711
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(929) 	(689)
Purchases of property, equipment and capitalized software . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(469) 	(562)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(165) 	154
Cash flows used for investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,533) 	(1,416)
Financing activities
Common share repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,691) 	(3,002)
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,024) 	(860)
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	557 	323
Repayments of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	(1,250)
Proceeds from short-term borrowings, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,797 	3,101
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,062 	1,784
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(398) 	(368)
Cash flows from (used for) financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	9,303 	(272)
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . 	(129) 	(5)
Increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,584 	1,541
Cash and cash equivalents, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,985 	10,866
Cash and cash equivalents, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$21,569 	$12,407
See Notes to the Condensed Consolidated Financial Statements
5

-- 9 of 36 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and
“the Company”) is a diversified health care company dedicated to helping people live healthier lives and helping
make the health system work better for everyone.
Through its diversified family of businesses, the Company leverages core competencies in data and health
information; advanced technology; and clinical expertise. These core competencies are deployed within two
distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and
health services operating under Optum.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally
Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its
subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements,
but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S.
Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would
substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements.
Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated
Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data”
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC
(2019 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring
adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best
estimates and judgments. The Company’s most significant estimates include medical costs payable and goodwill.
Certain of these estimates require the application of complex assumptions and judgments, often because they
involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any
change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue from Products
For the quarter ended March 31, 2020, the Company recognized revenue and cost of products sold for retail
pharmacy co-payments related to its OptumRx business. Revenue recognized in prior periods related to retail
pharmacy transactions excludes the member’s applicable co-payment. There was no impact on earnings from
operations, net earnings, earnings per share or total equity.
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU)
No. 2016-13, “Financial Instruments—Credit Losses (Topic 326)” (ASU 2016-13). ASU 2016-13 requires the
use of the current expected credit loss impairment model to develop an estimate of expected credit losses for
certain financial assets. ASU 2016-13 also requires expected credit losses on available-for-sale debt securities to
be recognized through an allowance for credit losses and revises certain disclosure requirements. The Company
adopted ASU 2016-13 on January 1, 2020 using a cumulative effect upon adoption approach. The adoption of
ASU 2016-13 was immaterial to the Company’s consolidated balance sheet, results of operations, equity and
cash flows.
6

-- 10 of 36 --

Under the current expected credit loss impairment model, the Company evaluates an available-for-sale debt
security for credit-related impairment by considering the present value of expected cash flows relative to a
security’s amortized cost, the extent to which fair value is less than amortized cost, the financial condition and
near-term prospects of the issuer and specific events or circumstances that may influence the operations of the
issuer. Credit-related impairments are recorded as an allowance, with an offset to investment and other income.
Non-credit related impairments are recorded through other comprehensive income. If the Company intends to
sell an impaired security, or will likely be required to sell a security before recovery of the entire amortized cost,
the entire impairment is included in net earnings.
The Company has determined that there have been no other recently adopted or issued accounting standards that
had, or will have, a material impact on its Condensed Consolidated Financial Statements.
2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
March 31, 2020
Debt securities—available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . 	$ 	3,146 	$ 	183 	$ 	(1) 	$ 	3,328
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	5,724 	214 	(20) 	5,918
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	17,923 	182 	(411) 	17,694
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . 	6,508 	260 	— 	6,768
Non-U.S. agency mortgage-backed securities . . . . . . . . . . 	1,932 	28 	(36) 	1,924
Total debt securities — available-for-sale . . . . . . . . . . . . . . . . . 	35,233 	867 	(468) 	35,632
Debt securities — held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . 	410 	9 	— 	419
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	31 	2 	— 	33
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	284 	— 	(1) 	283
Total debt securities — held-to-maturity . . . . . . . . . . . . . . . . . . 	725 	11 	(1) 	735
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	35,958 	$ 	878 	$ 	(469) 	$ 	36,367
December 31, 2019
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . . . . . 	$ 	3,502 	$ 	55 	$ 	(4) 	$ 	3,553
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	5,680 	251 	(5) 	5,926
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	17,910 	343 	(11) 	18,242
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . 	6,425 	109 	(6) 	6,528
Non-U.S. agency mortgage-backed securities . . . . . . . . . . 	1,811 	37 	(3) 	1,845
Total debt securities — available-for-sale . . . . . . . . . . . . . . . . . 	35,328 	795 	(29) 	36,094
Debt securities — held-to-maturity:
U.S. government and agency obligations . . . . . . . . . . . . . . 	402 	2 	— 	404
State and municipal obligations . . . . . . . . . . . . . . . . . . . . . 	32 	2 	— 	34
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	538 	— 	(1) 	537
Total debt securities — held-to-maturity . . . . . . . . . . . . . . . . . . 	972 	4 	(1) 	975
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	36,300 	$ 	799 	$ 	(30) 	$ 	37,069
7

-- 11 of 36 --

The Company held $1.7 billion and $2.0 billion of equity securities as of March 31, 2020 and December 31,
2019, respectively. The Company’s investments in equity securities primarily consist of employee savings plan
related investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair
values. Additionally, the Company’s investments included $1.4 billion of equity method investments in operating
businesses in the health care sector as of March 31, 2020 and December 31, 2019. The allowance for credit losses
on held-to-maturity securities at March 31, 2020 was not material.
The amortized cost and fair value of debt securities as of March 31, 2020, by contractual maturity, were as
follows:
Available-for-Sale 	Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3,010 	$ 	3,011 	$ 	319 	$ 	320
Due after one year through five years . . . . . . . . . . . . . . . . . . . . . . 	11,565 	11,604 	352 	359
Due after five years through ten years . . . . . . . . . . . . . . . . . . . . . . 	8,563 	8,669 	28 	28
Due after ten years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,655 	3,656 	26 	28
U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . . . . . 	6,508 	6,768 	— 	—
Non-U.S. agency mortgage-backed securities . . . . . . . . . . . . . . . . 	1,932 	1,924 	— 	—
Total debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	35,233 	$ 	35,632 	$ 	725 	$ 	735
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length
of time that individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 	12 Months or Greater 	Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
March 31, 2020
Debt securities — available-for-sale:
U.S. government and agency obligations . . . $ 	56 $ 	(1) $ 	— $ 	— 	$ 	56 $ 	(1)
State and municipal obligations . . . . . . . . . . 	810 	(20) 	— 	— 	810 	(20)
Corporate obligations . . . . . . . . . . . . . . . . . . 	9,294 	(382) 	391 	(29) 	9,685 	(411)
Non-U.S. agency mortgage-backed
securities . . . . . . . . . . . . . . . . . . . . . . . . . . 	841 	(33) 	30 	(3) 	871 	(36)
Total debt securities — available-for-sale . . . . . . $ 	11,001 $ 	(436) $ 	421 $ 	(32) $ 	11,422 $ 	(468)
December 31, 2019
Debt securities—available-for-sale:
U.S. government and agency obligations . . . $ 	616 $ 	(4) $ 	— $ 	— 	$ 	616 $ 	(4)
State and municipal obligations . . . . . . . . . . 	440 	(5) 	— 	— 	440 	(5)
Corporate obligations . . . . . . . . . . . . . . . . . . 	1,903 	(7) 	740 	(4) 	2,643 	(11)
U.S. agency mortgage-backed securities . . . 	657 	(3) 	333 	(3) 	990 	(6)
Non-U.S. agency mortgage-backed
securities . . . . . . . . . . . . . . . . . . . . . . . . . . 	406 	(3) 	— 	— 	406 	(3)
Total debt securities — available-for-sale . . . . . . $ 	4,022 $ 	(22) $ 	1,073 $ 	(7) $ 	5,095 $ 	(29)
The Company’s unrealized losses from debt securities as of March 31, 2020 were generated from approximately
10,000 positions out of a total of 32,000 positions. The Company believes that it will collect the timely principal
and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses
were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated
with these securities that impacted our assessment on collectability of principal and interest. At each reporting
8

-- 12 of 36 --

period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair
value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the
underlying credit quality and credit ratings of the issuers, and the potential economic impacts of COVID-19 on
the issuers, noting no significant credit deterioration since purchase. As of March 31, 2020, the Company did not
have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the
Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt
securities at March 31, 2020 was not material.
3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or
have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and
liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair
value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated
Financial Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items
measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
March 31, 2020
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	21,450 	$ 	119 	$ 	— 	$ 	21,569
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . 	3,143 	185 	— 	3,328
State and municipal obligations . . . . . . . . . . . . . . . . . 	— 	5,918 	— 	5,918
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . 	59 	17,385 	250 	17,694
U.S. agency mortgage-backed securities . . . . . . . . . . 	— 	6,768 	— 	6,768
Non-U.S. agency mortgage-backed securities . . . . . . 	— 	1,924 	— 	1,924
Total debt securities — available-for-sale . . . . . . . . . . . . . 	3,202 	32,180 	250 	35,632
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,394 	19 	— 	1,413
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . 	937 	1,890 	39 	2,866
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	26,983 	$ 	34,208 	$ 	289 	$ 	61,480
Percentage of total assets at fair value . . . . . . . . . . . . . . . . 	44% 	56% 	—% 	100%
December 31, 2019
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	10,837 	$ 	148 	$ 	— 	$ 	10,985
Debt securities — available-for-sale:
U.S. government and agency obligations . . . . . . . . . . 	3,369 	184 	— 	3,553
State and municipal obligations . . . . . . . . . . . . . . . . . 	— 	5,926 	— 	5,926
Corporate obligations . . . . . . . . . . . . . . . . . . . . . . . . . 	70 	17,923 	249 	18,242
U.S. agency mortgage-backed securities . . . . . . . . . . 	— 	6,528 	— 	6,528
Non-U.S. agency mortgage-backed securities . . . . . . 	— 	1,845 	— 	1,845
Total debt securities — available-for-sale . . . . . . . . . . . . . 	3,439 	32,406 	249 	36,094
Equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,734 	22 	— 	1,756
Assets under management . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,123 	1,918 	35 	3,076
Total assets at fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	17,133 	$ 	34,494 	$ 	284 	$ 	51,911
Percentage of total assets at fair value . . . . . . . . . . . . . . . . 	33% 	66% 	1% 	100%
9

-- 13 of 36 --

There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended
March 31, 2020 or 2019.
The following table presents a summary of fair value measurements by level and carrying values for certain
financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance
Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
March 31, 2020
Debt securities — held-to-maturity . . . . . . . . . . . . . $ 	556 $ 	91 $ 	88 $ 	735 $ 	725
Long-term debt and other financing obligations . . . $ 	— $ 	45,272 $ 	— $ 	45,272 $ 	40,394
December 31, 2019
Debt securities — held-to-maturity . . . . . . . . . . . . . $ 	541 $ 	181 $ 	253 $ 	975 $ 	972
Long-term debt and other financing obligations . . . $ 	— $ 	45,078 $ 	— $ 	45,078 $ 	40,278
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a
nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company
records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded
during either the three months ended March 31, 2020 or 2019.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the three months ended
March 31:
(in millions) 	2020 	2019
Medical costs payable, beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 21,690 	$ 19,891
Acquisitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	— 	35
Reported medical costs:
Current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	41,580 	39,239
Prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(580) 	(300)
Total reported medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	41,000 	38,939
Medical payments:
Payments for current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(23,471) 	(22,973)
Payments for prior years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(16,447) 	(14,753)
Total medical payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(39,918) 	(37,726)
Medical costs payable, end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 22,772 	$ 21,139
For the three months ended March 31, 2020, prior years medical cost reserve development was primarily driven
by lower than expected health system utilization. For the three months ended March 31, 2019, the prior years
medical cost reserve development included no individual factors that were significant. Medical costs payable
included reserves for claims incurred by insured customers but not yet reported to the Company of $14.3 billion
and $13.8 billion at March 31, 2020 and December 31, 2019, respectively.
10

-- 14 of 36 --

5. 	Short-Term Borrowings and Long-Term Debt
Short-term borrowings and senior unsecured long-term debt consisted of the following:
March 31, 2020 	December 31, 2019
(in millions, except percentages) Par
Value Carrying
Value Fair
Value Par
Value Carrying
Value Fair
Value
Commercial paper . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	1,214 $ 	1,213 $ 	1,213 $ 	400 $ 	400 $ 	400
Bank credit facilities . . . . . . . . . . . . . . . . . . . . . . . . 	10,000 	10,000 	10,000 	— 	— 	—
2.700% notes due July 2020 . . . . . . . . . . . . . . . . . . 	1,500 	1,500 	1,500 	1,500 	1,499 	1,506
Floating rate notes due October 2020 . . . . . . . . . . . 	300 	300 	296 	300 	300 	300
3.875% notes due October 2020 . . . . . . . . . . . . . . . 	450 	452 	452 	450 	450 	455
1.950% notes due October 2020 . . . . . . . . . . . . . . . 	900 	899 	900 	900 	899 	900
4.700% notes due February 2021 . . . . . . . . . . . . . . 	400 	406 	407 	400 	403 	410
2.125% notes due March 2021 . . . . . . . . . . . . . . . . 	750 	749 	750 	750 	749 	753
Floating rate notes due June 2021 . . . . . . . . . . . . . . 	350 	349 	347 	350 	349 	350
3.150% notes due June 2021 . . . . . . . . . . . . . . . . . . 	400 	399 	406 	400 	399 	407
3.375% notes due November 2021 . . . . . . . . . . . . . 	500 	510 	512 	500 	501 	512
2.875% notes due December 2021 . . . . . . . . . . . . . 	750 	768 	764 	750 	753 	765
2.875% notes due March 2022 . . . . . . . . . . . . . . . . 	1,100 	1,114 	1,130 	1,100 	1,087 	1,121
3.350% notes due July 2022 . . . . . . . . . . . . . . . . . . 	1,000 	998 	1,034 	1,000 	998 	1,036
2.375% notes due October 2022 . . . . . . . . . . . . . . . 	900 	896 	912 	900 	896 	911
0.000% notes due November 2022 . . . . . . . . . . . . . 	15 	13 	14 	15 	13 	14
2.750% notes due February 2023 . . . . . . . . . . . . . . 	625 	646 	640 	625 	624 	638
2.875% notes due March 2023 . . . . . . . . . . . . . . . . 	750 	797 	777 	750 	770 	770
3.500% notes due June 2023 . . . . . . . . . . . . . . . . . . 	750 	747 	788 	750 	747 	786
3.500% notes due February 2024 . . . . . . . . . . . . . . 	750 	746 	794 	750 	746 	792
2.375% notes due August 2024 . . . . . . . . . . . . . . . . 	750 	747 	767 	750 	747 	760
3.750% notes due July 2025 . . . . . . . . . . . . . . . . . . 	2,000 	1,991 	2,161 	2,000 	1,990 	2,161
3.700% notes due December 2025 . . . . . . . . . . . . . 	300 	298 	323 	300 	298 	325
3.100% notes due March 2026 . . . . . . . . . . . . . . . . 	1,000 	996 	1,056 	1,000 	996 	1,048
3.450% notes due January 2027 . . . . . . . . . . . . . . . 	750 	746 	804 	750 	746 	804
3.375% notes due April 2027 . . . . . . . . . . . . . . . . . 	625 	620 	668 	625 	620 	667
2.950% notes due October 2027 . . . . . . . . . . . . . . . 	950 	939 	992 	950 	939 	988
3.850% notes due June 2028 . . . . . . . . . . . . . . . . . . 	1,150 	1,143 	1,281 	1,150 	1,142 	1,269
3.875% notes due December 2028 . . . . . . . . . . . . . 	850 	843 	953 	850 	843 	941
2.875% notes due August 2029 . . . . . . . . . . . . . . . . 	1,000 	1,104 	1,047 	1,000 	993 	1,029
4.625% notes due July 2035 . . . . . . . . . . . . . . . . . . 	1,000 	992 	1,190 	1,000 	992 	1,215
5.800% notes due March 2036 . . . . . . . . . . . . . . . . 	850 	838 	1,107 	850 	838 	1,129
6.500% notes due June 2037 . . . . . . . . . . . . . . . . . . 	500 	492 	691 	500 	492 	712
6.625% notes due November 2037 . . . . . . . . . . . . . 	650 	641 	910 	650 	641 	940
6.875% notes due February 2038 . . . . . . . . . . . . . . 	1,100 	1,077 	1,613 	1,100 	1,076 	1,631
3.500% notes due August 2039 . . . . . . . . . . . . . . . . 	1,250 	1,241 	1,348 	1,250 	1,241 	1,313
5.700% notes due October 2040 . . . . . . . . . . . . . . . 	300 	296 	405 	300 	296 	396
5.950% notes due February 2041 . . . . . . . . . . . . . . 	350 	345 	484 	350 	345 	475
4.625% notes due November 2041 . . . . . . . . . . . . . 	600 	589 	742 	600 	589 	716
4.375% notes due March 2042 . . . . . . . . . . . . . . . . 	502 	484 	601 	502 	484 	580
3.950% notes due October 2042 . . . . . . . . . . . . . . . 	625 	608 	711 	625 	607 	688
4.250% notes due March 2043 . . . . . . . . . . . . . . . . 	750 	735 	885 	750 	735 	856
4.750% notes due July 2045 . . . . . . . . . . . . . . . . . . 	2,000 	1,973 	2,547 	2,000 	1,973 	2,463
4.200% notes due January 2047 . . . . . . . . . . . . . . . 	750 	738 	881 	750 	738 	861
4.250% notes due April 2047 . . . . . . . . . . . . . . . . . 	725 	717 	853 	725 	717 	839
3.750% notes due October 2047 . . . . . . . . . . . . . . . 	950 	934 	1,050 	950 	934 	1,023
4.250% notes due June 2048 . . . . . . . . . . . . . . . . . . 	1,350 	1,330 	1,592 	1,350 	1,330 	1,569
4.450% notes due December 2048 . . . . . . . . . . . . . 	1,100 	1,086 	1,333 	1,100 	1,086 	1,316
3.700% notes due August 2049 . . . . . . . . . . . . . . . . 	1,250 	1,235 	1,385 	1,250 	1,235 	1,344
3.875% notes due August 2059 . . . . . . . . . . . . . . . . 	1,250 	1,229 	1,372 	1,250 	1,228 	1,350
Total short-term borrowings and long-term debt . . $ 50,631 $ 50,509 $ 55,388 $ 39,817 $ 39,474 $ 44,234
11

-- 15 of 36 --

The Company’s long-term debt obligations also included $1.1 billion and $1.2 billion of other financing
obligations, of which $309 million and $322 million were classified as current as of March 31, 2020 and
December 31, 2019, respectively.
Commercial Paper and Bank Credit Facilities
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through
broker-dealers. As of March 31, 2020, the Company’s outstanding commercial paper had a weighted average
annual interest rate of 2.4%.
The Company has $4.4 billion five-year, $4.4 billion three-year and $3.8 billion 364-day revolving bank credit
facilities with 25 banks, which mature in December 2024, December 2022 and December 2020, respectively.
These facilities provide liquidity support for the Company’s commercial paper program and are available for
general corporate purposes. The annual interest rates, which are variable based on term, are calculated based on
the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured
credit ratings. As of March 31, 2020, the Company had drawn $1.8 billion, $4.4 billion and $3.8 billion at annual
interest rates of 1.6%, 1.6% and 1.7% on its $4.4 billion five-year, $4.4 billion three-year and $3.8 billion
364-day revolving bank credit facilities, respectively.
Debt Covenants
The Company’s bank credit facilities contain various covenants, including covenants requiring the Company to
maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. The Company was in
compliance with its debt covenants as of March 31, 2020.
6. 	Commitments and Contingencies
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and
regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy
organizations, customers and regulators, relating to the Company’s businesses, including management and
administration of health benefit plans and other services. These matters include medical malpractice,
employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits
coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate.
Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to
predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines,
penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large
number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in
business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those
matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and
reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare
and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the
Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government
Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of
Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of
Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental
authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by
12

-- 16 of 36 --

applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of
the Company’s businesses have been reviewed or are currently under review, including for, among other matters,
compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected
certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding
practices of and supporting documentation maintained by health care providers and such audits may result in
retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a
lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s
complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment
submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part
the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s counterclaims, which were
filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s
motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The
Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.
13

-- 17 of 36 --

7. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more
information on the Company’s segments see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2019 10-K.
The following tables present reportable segment financial information:
Optum
(in millions) 	UnitedHealthcare OptumHealth OptumInsight OptumRx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Three Months Ended March 31,
2020
Revenues — unaffiliated customers:
Premiums . . . . . . . . . . . . . . . . . $ 	48,593 	$ 	2,047 	$ 	— $ 	— $ 	— $ 	2,047 $ 	— $ 	50,640
Products . . . . . . . . . . . . . . . . . . 	— 	9 	29 	8,393 	— 	8,431 	— 	8,431
Services . . . . . . . . . . . . . . . . . . . 	2,278 	1,548 	891 	268 	— 	2,707 	— 	4,985
Total revenues — unaffiliated
customers . . . . . . . . . . . . . . . . . . . 	50,871 	3,604 	920 	8,661 	— 	13,185 	— 	64,056
Total revenues — affiliated
customers . . . . . . . . . . . . . . . . . . . 	— 	5,452 	1,562 	12,876 	(404) 	19,486 	(19,486) 	—
Investment and other income . . . . . . 	197 	136 	12 	20 	— 	168 	— 	365
Total revenues . . . . . . . . . . . . . . . . . . $ 	51,068 	$ 	9,192 	$ 	2,494 $ 	21,557 $ 	(404)$ 32,839 $ 	(19,486) $ 	64,421
Earnings from operations . . . . . . . . . $ 	2,888 	$ 	712 	$ 	536 $ 	860 $ 	— $ 	2,108 $ 	— $ 	4,996
Interest expense . . . . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(437) 	(437)
Earnings before income taxes . . . . . . $ 	2,888 	$ 	712 	$ 	536 $ 	860 $ 	— $ 	2,108 $ 	(437) $ 	4,559
Three Months Ended March 31,
2019
Revenues — unaffiliated customers:
Premiums . . . . . . . . . . . . . . . . . $ 	46,501 	$ 	1,012 	$ 	— $ 	— $ 	— $ 	1,012 $ 	— $ 	47,513
Products . . . . . . . . . . . . . . . . . . 	— 	8 	23 	8,041 	— 	8,072 	— 	8,072
Services . . . . . . . . . . . . . . . . . . . 	2,141 	1,274 	754 	149 	— 	2,177 	— 	4,318
Total revenues — unaffiliated
customers . . . . . . . . . . . . . . . . . . . 	48,642 	2,294 	777 	8,190 	— 	11,261 	— 	59,903
Total revenues — affiliated
customers . . . . . . . . . . . . . . . . . . . 	— 	4,287 	1,407 	9,613 	(359) 	14,948 	(14,948) 	—
Investment and other income . . . . . . 	254 	132 	5 	14 	— 	151 	— 	405
Total revenues . . . . . . . . . . . . . . . . . . $ 	48,896 	$ 	6,713 	$ 	2,189 $ 	17,817 $ 	(359)$ 26,360 $ 	(14,948) $ 	60,308
Earnings from operations . . . . . . . . . $ 	2,954 	$ 	626 	$ 	432 $ 	820 $ 	— $ 	1,878 $ 	— $ 	4,832
Interest expense . . . . . . . . . . . . . . . . . 	— 	— 	— 	— 	— 	— 	(400) 	(400)
Earnings before income taxes . . . . . . $ 	2,954 	$ 	626 	$ 	432 $ 	820 $ 	— $ 	1,878 $ 	(400) $ 	4,432
14

-- 18 of 36 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial
Statements and Notes and with our 2019 10-K, including the Consolidated Financial Statements and Notes in
Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates
otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this
Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth
Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s
Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding
financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to
differ materially from the results discussed or implied in the forward-looking statements. A description of some
of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2019 10-K and in the discussion
below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company dedicated to helping people live healthier lives and
helping make the health system work better for everyone. Through our diversified family of businesses, we
leverage core competencies in data and health information, advanced technology, and clinical expertise, focused
on improving health outcomes, lowering health care costs and creating a better experience for patients, their
caregivers and physicians. These core competencies are deployed within our two distinct, but strategically
aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating
under Optum.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” in our 2019 10-K and additional
information on our segments can be found in this Item 2 and in Note 7 of Notes to the Condensed Consolidated
Financial Statements included in Part I, Item 1 of this report.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic is rapidly evolving and the ultimate impact on our business, results of operations,
financial condition and cash flows is uncertain and difficult to predict. For additional information regarding risks
and uncertainties relating to COVID-19, see “Risk Factors” in Part II, Item 1A of this report. Specific trends and
uncertainties related to our two business platforms are as follows:
UnitedHealthcare. We have expanded benefit coverage in areas such as COVID-19 testing and treatment,
telemedicine, and pharmacy benefits; offered additional enrollment opportunities to those who previously
declined employer-sponsored offerings; extended certain premium payment terms for customers experiencing
financial hardship; simplified administrative practices; and began accelerating payments to care providers, all
with the aim of assisting our customers, providers and members in addressing the COVID-19 crisis. Potential
economic costs, including cost of care and loss of commercial membership due to higher rates of unemployment,
may initially be more than offset by temporary deferrals of elective care and increased membership in Medicaid
and individual programs. Following the crisis, consumer demand for care is expected to return, resulting in
potentially increased future medical costs. Depending on the pacing and intensity of the virus, as well as the
duration of policies and initiatives to address COVID-19, such as stay-at-home and social distancing guidelines,
the ultimate impact is uncertain.
15

-- 19 of 36 --

Optum. The reduction of elective and routine procedures also impacts the Optum business. For example, most
traditional procedure work at our ambulatory surgery centers has been postponed, while our capitated care
delivery businesses have experienced lower care demand. COVID-19 will also continue to influence customer
and consumer behavior, both during and after the pandemic, which could impact how care is delivered and the
manner in which consumers wish to receive their prescription drugs or infusion services. The impact of
COVID-19 on our care provider and payer clients could impact the volume and types of services that Optum
provides, as well as the pacing of potential new business opportunities. As a result of the dynamic situation and
broad-reaching impact to the health system, the ultimate impact of COVID-19 is uncertain.
Business Trends
Our businesses participate in the United States, South American and certain other international health markets.
Overall spending on health care is impacted by inflation; utilization; medical technology and pharmaceutical
advancement; regulatory requirements; demographic trends in the population and national interest in health and
well-being. The rate of market growth may be affected by a variety of factors, including macro-economic
conditions, such as the economic impact of COVID-19, and regulatory changes, which could impact our results
of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs,
including any impact from the Health Insurance Tax. We frequently evaluate and adjust our approach in each of
the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness
and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio
(MLR) thresholds. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We
expect broad-based competition to continue as the industry adapts to individual and employer needs amid reform
changes. Pricing for contracts that cover some portion of calendar year 2021 will reflect the permanent repeal of
the Health Insurance Tax.
Government programs in the public and senior sector tend to receive lower rates of increase than the commercial
market due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization
and prescription drug costs. We endeavor to mitigate those increases by engaging physicians and consumers with
information and helping them make clinically sound choices, with the objective of helping them achieve high
quality, affordable care. The uncertain impact of COVID-19 may impact our ability to estimate medical costs
payable, which could result in increased variability to medical cost reserve development in future periods.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of regulatory trends and uncertainties. For additional information
regarding regulatory trends and uncertainties, see Part I, Item 1 “Business—Government Regulation,” Part 1,
Item 1A, “Risk Factors,” Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in our 2019 10-K and “Risk Factors” in Part II, Item 1A of this report.
Medicare Advantage Rates. Final 2021 Medicare Advantage rates resulted in an increase in industry base rates
of approximately 1.7%, short of the industry forward medical cost trend, creating continued pressure in the
Medicare Advantage program.
Affordable Care Act (ACA) Tax. After a moratorium in 2019, the industry-wide amount of the Health Insurance
Tax for 2020, which is primarily borne by customers, is $15.5 billion, with our portion being approximately
$3.0 billion. The return of the tax impacts year-over-year comparability of our financial statements, including
revenues, operating costs, medical care ratio (MCR), operating cost ratio, effective tax rate and cash flows from
operations. The ACA Tax was permanently repealed by Congress, effective January 1, 2021.
16

-- 20 of 36 --

SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select first quarter 2020 year-over-year operating comparisons to first quarter 2019.
• 	Consolidated revenues grew 7%, UnitedHealthcare revenues grew 4% and Optum revenues grew 25%.
• 	UnitedHealthcare served 670,000 fewer people domestically primarily due to expected attrition in
commercial group and the proactive withdrawal from a Medicaid market.
• 	Consolidated earnings from operations increased 3%, including a decrease of 2% at UnitedHealthcare
and an increase of 12% at Optum.
• 	Diluted earnings per common share decreased 1% to $3.52.
• 	Cash flows from operations for the three months ended March 31, 2020 were $2.9 billion.
• 	Return on equity was 23.6%.
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)
Three Months Ended
March 31, Increase/
(Decrease)
2020 	2019 	2020 vs. 2019
Revenues:
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$50,640 	$47,513 	$3,127 	7%
Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,431 	8,072 	359 	4
Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,985 	4,318 	667 	15
Investment and other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	365 	405 	(40) (10)
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	64,421 	60,308 	4,113 	7
Operating costs:
Medical costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	41,000 	38,939 	2,061 	5
Operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,015 	8,517 	1,498 	18
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7,687 	7,381 	306 	4
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	723 	639 	84 	13
Total operating costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	59,425 	55,476 	3,949 	7
Earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,996 	4,832 	164 	3
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(437) 	(400) 	(37) 	9
Earnings before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,559 	4,432 	127 	3
Provision for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,094) 	(875) 	(219) 	25
Net earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	3,465 	3,557 	(92) 	(3)
Earnings attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(83) 	(90) 	7 	(8)
Net earnings attributable to UnitedHealth Group common shareholders . . . . . . . . . . . 	$ 3,382 	$ 3,467 	$ 	(85) 	(2)%
Diluted earnings per share attributable to UnitedHealth Group common
shareholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	3.52 	$ 	3.56 	$ (0.04) 	(1)%
Medical care ratio (a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	81.0% 	82.0% 	(1.0)%
Operating cost ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	15.5 	14.1 	1.4
Operating margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.8 	8.0 	(0.2)
Tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	24.0 	19.7 	4.3
Net earnings margin (b) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5.2 	5.7 	(0.5)
Return on equity (c) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	23.6% 	26.8% 	(3.2)%
(a) 	Medical care ratio is calculated as medical costs divided by premium revenue.
(b) 	Net earnings margin attributable to UnitedHealth Group shareholders.
(c) 	Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common
shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the
shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the
end of each of the quarters in the year presented.
17

-- 21 of 36 --

2020 RESULTS OF OPERATIONS COMPARED TO 2019 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenue
The increases in revenue were primarily driven by the increase in the number of individuals served through
Medicare Advantage; pricing trends; and acquisition and organic growth across the Optum business, primarily
due to expansion in pharmacy care services and care delivery.
Medical Costs and MCR
Medical costs increased due to growth in people served through Medicare Advantage, medical cost trends and
calendar day impacts, partially offset by decreased people served in Medicaid due to a proactive market
withdrawal and increased prior year favorable medical cost development. The MCR decreased primarily due to
the revenue effects of the return of the Health Insurance Tax, partially offset by calendar day impacts.
Operating Cost Ratio
The operating cost ratio increased primarily due to the impact of the return of the Health Insurance Tax and
changes in business mix, partially offset by effective operating cost management.
Income Tax Rate
Our effective tax rate increased primarily due to the impact of the return of the nondeductible Health Insurance
Tax.
Reportable Segments
See Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report
for more information on our segments. We utilize various metrics to evaluate and manage our reportable
segments, including individuals served by UnitedHealthcare by major market segment and funding arrangement,
people served by OptumHealth and adjusted scripts for OptumRx. These metrics are the main drivers of revenue,
earnings and cash flows at each business. The metrics also allow management and investors to evaluate and
understand business mix, customer penetration and pricing trends when comparing the metrics to revenue by
segment.
18

-- 22 of 36 --

The following table presents a summary of the reportable segment financial information:
Three Months Ended
March 31, Increase/
(Decrease)
(in millions, except percentages) 	2020 	2019 	2020 vs. 2019
Revenues
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 51,068 	$ 48,896 	$ 2,172 	4%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	9,192 	6,713 	2,479 	37
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,494 	2,189 	305 	14
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21,557 	17,817 	3,740 	21
Optum eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(404) 	(359) 	(45) 13
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	32,839 	26,360 	6,479 	25
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(19,486) 	(14,948) 	(4,538) 30
Consolidated revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 64,421 	$ 60,308 	$ 4,113 	7%
Earnings from operations
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	2,888 	$ 	2,954 	$ 	(66) 	(2)%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	712 	626 	86 	14
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	536 	432 	104 	24
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	860 	820 	40 	5
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,108 	1,878 	230 	12
Consolidated earnings from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	4,996 	$ 	4,832 	$ 	164 	3%
Operating margin
UnitedHealthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5.7% 	6.0% 	(0.3)%
OptumHealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.7 	9.3 	(1.6)
OptumInsight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	21.5 	19.7 	1.8
OptumRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4.0 	4.6 	(0.6)
Optum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	6.4 	7.1 	(0.7)
Consolidated operating margin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	7.8% 	8.0% 	(0.2)%
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
March 31, Increase/
(Decrease)
(in millions, except percentages) 	2020 	2019 	2020 vs. 2019
UnitedHealthcare Employer & Individual . . . . . . . . . . . . . . . . . . . . . . . . . $ 	14,280 $ 	14,084 $ 	196 	1%
UnitedHealthcare Medicare & Retirement . . . . . . . . . . . . . . . . . . . . . . . . 	23,152 	21,096 	2,056 10
UnitedHealthcare Community & State . . . . . . . . . . . . . . . . . . . . . . . . . . . 	11,453 	11,182 	271 	2
UnitedHealthcare Global . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	2,183 	2,534 	(351) (14)
Total UnitedHealthcare revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 	51,068 $ 	48,896 $ 	2,172 	4%
19

-- 23 of 36 --

The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major
market segment and funding arrangement:
March 31, Increase/
(Decrease)
(in thousands, except percentages) 	2020 	2019 	2020 vs. 2019
Commercial:
Risk-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	8,215 	8,340 	(125) (1)%
Fee-based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	18,825 	19,175 	(350) (2)
Total commercial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	27,040 	27,515 	(475) (2)
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,575 	5,165 	410 	8
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,880 	6,425 	(545) (8)
Medicare Supplement (Standardized) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,440 	4,500 	(60) (1)
Total public and senior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	15,895 	16,090 	(195) (1)
Total UnitedHealthcare — domestic medical . . . . . . . . . . . . . . . . . . . . . . . 	42,935 	43,605 	(670) (2)
International . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	5,605 	6,125 	(520) (8)
Total UnitedHealthcare — medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	48,540 	49,730 	(1,190) (2)%
Supplemental Data:
Medicare Part D stand-alone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	4,150 	4,480 	(330) (7)%
Fee-based and risk-based commercial business decreased primarily due to expected attrition. Medicare
Advantage increased due to growth in people served through individual Medicare Advantage plans. The decrease
in people served through Medicaid was primarily driven by the proactive withdrawal from a market as well as by
states managing eligibility, partially offset by increases in Dual Special Needs Plans. The decrease in people
served internationally is a result of our continued affordability efforts and underwriting discipline.
UnitedHealthcare’s revenue increased due to growth in the number of individuals served through Medicare
Advantage, a greater mix of people with higher acuity needs and the return of the Health Insurance Tax, partially
offset by a decrease in the number of individuals served through the commercial and Medicaid businesses.
Earnings from operations decreased primarily due to the return of the Health Insurance Tax and calendar day
impacts, partially offset by the factors impacting revenue.
Optum
Total revenues and earnings from operations increased as each segment reported increased revenues and earnings
from operations as a result of productivity and overall cost management initiatives in addition to the factors
discussed below.
The results by segment were as follows:
OptumHealth
Revenue and earnings from operations increased at OptumHealth primarily due to acquisitions and organic
growth in care delivery. OptumHealth served approximately 96 million people as of March 31, 2020 compared to
93 million people as of March 31, 2019.
OptumInsight
Revenue and earnings from operations at OptumInsight increased primarily due to organic growth and
acquisitions in managed services.
20

-- 24 of 36 --

OptumRx
Revenue at OptumRx and the corresponding eliminations increased due to the inclusion of retail pharmacy
co-payments. See Note 1 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1
of this report for further detail. Revenue at OptumRx also increased due to organic and acquisition growth in
specialty pharmacy and new client wins, partially offset by an expected large client transition. Earnings from
operations increased primarily due to improved supply chain management. OptumRx fulfilled 339 million
adjusted scripts in the first quarter of 2020 and 2019, with organic growth in adjusted scripts being offset by the
expected large client transition.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Three Months Ended
March 31, 	Increase/(Decrease)
(in millions) 	2020 	2019 	2020 vs. 2019
Sources of cash:
Cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 2,943 	$ 3,234 	$ 	(291)
Issuances of short-term borrowings and long-term debt, net of
repayments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	10,797 	1,851 	8,946
Proceeds from common stock issuances . . . . . . . . . . . . . . . . . . . . . . . 	557 	323 	234
Customer funds administered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	1,062 	1,784 	(722)
Sales and maturities of investments, net of purchases . . . . . . . . . . . . 	30 	— 	30
Total sources of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	15,389 	7,192
Uses of cash:
Common stock repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,691) 	(3,002) 	1,311
Cash paid for acquisitions, net of cash assumed . . . . . . . . . . . . . . . . . 	(929) 	(689) 	(240)
Purchases of investments, net of sales and maturities . . . . . . . . . . . . 	— 	(319) 	319
Purchases of property, equipment and capitalized software . . . . . . . . 	(469) 	(562) 	93
Cash dividends paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(1,024) 	(860) 	(164)
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(563) 	(214) 	(349)
Total uses of cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(4,676) 	(5,646)
Effect of exchange rate changes on cash and cash equivalents . . . . . . . . . 	(129) 	(5) 	(124)
Net increase in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . 	$10,584 	$ 1,541 	$ 	9,043
2020 Cash Flows Compared to 2019 Cash Flows
Decreased cash flows provided by operating activities were primarily driven by changes in working capital
accounts. Other significant changes in sources or uses of cash year-over-year included increased short-term
borrowings and decreased common stock repurchases, partially offset by a decrease in customer funds
administered.
Financial Condition
As of March 31, 2020, our cash, cash equivalent, available-for-sale debt securities and equity securities balances
of $58.9 billion included approximately $21.6 billion of cash and cash equivalents (of which $10.9 billion was
available for general corporate use), $35.6 billion of debt securities and $1.7 billion of investments in equity
securities. Cash available for general corporate use was intentionally higher than previous periods as a prudent
21

-- 25 of 36 --

response to more volatile financial markets. Given the significant portion of our portfolio held in cash and cash
equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material
impact on our liquidity or capital position. Our available-for-sale debt portfolio had a weighted-average duration
of 3.5 years and a weighted-average credit rating of “Double A” as of March 31, 2020. When multiple credit
ratings are available for an individual security, the average of the available ratings is used to determine the
weighted-average credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate
use, our capital resources and uses of liquidity are as follows:
Commercial Paper and Bank Credit Facilities. Our revolving bank credit facilities provide liquidity support for
our commercial paper borrowing program, which facilitates the private placement of unsecured debt through
independent broker-dealers, and are available for general corporate purposes. For more information on our
commercial paper and bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial
Statements included in Part I, Item 1 of this report.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a
defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of March 31, 2020, our debt to
debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 44%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate
purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for
share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
Credit Ratings. Our credit ratings as of March 31, 2020 were as follows:
Moody’s 	S&P Global 	Fitch 	A.M. Best
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Senior unsecured debt . . . . . . . . . . . . 	A3 	Stable 	A+ 	Stable 	A 	Stable 	A- 	Positive
Commercial paper . . . . . . . . . . . . . . . 	P-2 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1 	n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our
profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions,
regulatory requirements and economic and market conditions, including the impacts of COVID-19 and related
governmental market stabilization programs. A significant downgrade in our credit ratings or adverse conditions
in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the three months ended March 31, 2020, we repurchased 6 million shares at
an average price of $271.32 per share. As of March 31, 2020, we had Board authorization to purchase up to
66 million shares of our common stock.
Dividends. Our quarterly cash dividend to shareholders reflects an annual dividend rate of $4.32 per share.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements in Part II,
Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” in Part II, Item 7 in our 2019 10-K.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
A summary of future obligations under our various contractual obligations and commitments as of December 31,
2019 was disclosed in our 2019 10-K. During the three months ended March 31, 2020, there were no material
22

-- 26 of 36 --

changes to this previously disclosed information outside the ordinary course of business. However, we
continually evaluate opportunities to expand our operations, including through internal development of new
products, programs and technology applications and acquisitions.
RECENTLY ISSUED ACCOUNTING STANDARDS
See Note 1 of Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report for a
discussion of new accounting pronouncements that affect us.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions
and estimates, which we believe are reasonable and prudent based on the available facts and circumstances.
These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance
sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on
historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection
of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from
our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our
critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” in Part II, Item 7 in our 2019 10-K. For a detailed discussion of our significant accounting policies,
see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2019 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-
looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities
law. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,”
“should” and similar expressions identify forward-looking statements. These statements may contain information
about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results
could differ materially from those that management expects, depending on the outcome of certain factors
including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the
COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in
existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the
risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting
revenue; reductions in revenue or delays to cash flows received under government programs; changes in
Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to
maintain effective and efficient information systems or if our technology products do not operate as intended;
cyber-attacks, other privacy/data security incidents, or our failure to comply with related regulations; risks and
uncertainties associated with the pharmacy benefits management industry; competitive pressures; changes in or
challenges to our public sector contract awards; our ability to contract on competitive terms with physicians,
hospitals and other service providers; failure to achieve targeted operating cost productivity improvements;
increases in costs and other liabilities associated with litigation, government investigations, audits or reviews;
failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic
transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment
portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient
funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to
total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing
shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that
may affect our business operations, financial condition and results of operations more fully in our filings with the
SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not
23

-- 27 of 36 --

guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are
difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this
document or any of our prior communications. You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market
sectors and debt across maturities, as well as by endeavoring to match our floating-rate assets and liabilities over
time, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments
in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield
curve by 1% point or 2% points as of March 31, 2020 on our investment income and interest expense per annum,
and the fair value of our investments and debt (in millions, except percentages):
March 31, 2020
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum (a)
Interest
Expense Per
Annum (a)
Fair Value of
Financial
Assets (b)
Fair Value of
Financial
Liabilities
2% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	$ 	491 	$ 	404 	$ 	(2,514) $ 	(6,673)
1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	246 	202 	(1,250) 	(3,628)
(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(160) 	(202) 	784 	3,735
(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 	(160) 	(267) 	877 	4,694
(a) 	Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of
March 31, 2020, the assumed hypothetical change in interest rates does not reflect the full 100 and 200 basis
point reduction in interest income or the full 200 basis point reduction in interest expense, as the rate cannot
fall below zero.
(b) 	As of March 31, 2020, some of our investments had interest rates below 2% so the assumed hypothetical
change in the fair value of investments does not reflect the full 100 and 200 basis point reduction.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information
required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed,
summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and
communicated to our management, including our principal executive officer and principal financial officer, as
appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision
and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the
design and operation of our disclosure controls and procedures as of March 31, 2020. Based upon that evaluation,
our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective at the reasonable assurance level as of March 31, 2020.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2020
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
24

-- 28 of 36 --

PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 6 of Notes to the
Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in
Part I, Item 1A, “Risk Factors” of our 2019 10-K, which could materially affect our business, financial condition
or future results. The risks described in our 2019 10-K and in this Item 1A, are not the only risks facing us.
Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may
materially adversely affect our business, financial condition or future results.
There have been no other material changes to the risk factors disclosed in our 2019 10-K except that we have
added the following risk factor to provide details on our risks associated with COVID-19:
We are subject to risks associated with public health crises, large-scale medical emergencies and pandemics,
such as the COVID-19 pandemic, which could have a material adverse effect on our business, results of
operations, financial condition and financial performance.
The rapidly developing COVID-19 global health crisis is having major impacts on health systems, businesses,
governments and customer and consumer activities. UnitedHealth Group continues to mobilize the full strength
of its resources to deliver the best care for patients, support for its members and care provider partners, and
deliver innovative solutions and support for the communities we serve and the entire health system. The impact
to our business is primarily dependent upon the ultimate pacing, intensity and duration of the crisis, factors which
we cannot predict at this time. These factors will drive the related treatment, testing, coverage and other services
we provide for the people we serve. The health system has recently experienced deferrals of elective care, which
impacts both the UnitedHealthcare and Optum businesses through decreased utilization of health care services.
As the crisis abates, we may experience an increase in medical care costs as people seek care which was deferred
during the pandemic and individuals with chronic conditions may require additional care needs resulting from
missed treatments. There can be no assurance that the premiums and fees we charge will be sufficient to cover
the medical and administrative costs associated with COVID-19. In addition, we may experience reduced
demand for certain services Optum provides to care providers and health plans as a result of reduced clinical and
claims activity and changes in business priorities resulting from COVID-19. We cannot at this time measure the
impact or duration of changing customer, consumer and member behavior to our overall business.
Governmental policies and initiatives to address COVID-19 have resulted in our customers having to close or
severely curtail their operations. Among other impacts, we may experience loss of commercial membership due
to customer reductions in workforce and an adverse impact on the timing and collectability of premium
payments. In addition, governments have modified, and may continue to modify, regulatory standards around
various aspects of health care in response to COVID-19, and these rapidly changing standards may create
challenges for us to ensure timely compliance and meet various contractual obligations.
Disruptions in public and private infrastructure, including supply chains providing medical supplies and
pharmaceutical products, could adversely disrupt our business operations. Additionally, the enactment of
emergency powers by governments could disrupt our business operations, including restricting pharmaceuticals
or other supplies, and could increase the risk of shortages of necessary items.
We have transitioned a significant number of our team members to at-home work environments in an effort to
mitigate the spread of COVID-19. This transition may increase our operating costs and effectiveness, including
25

-- 29 of 36 --

our ability to maintain service levels and ratings, and exacerbate certain risks to our business, including demand
for information technology resources, increased vulnerabilities to cybersecurity attacks, and increased risk of
unauthorized dissemination of sensitive personal information or proprietary or confidential information about us,
our customers or our members.
The COVID-19 crisis has also adversely impacted global access to capital and caused significant volatility in
financial markets. Significant deterioration of the U.S. and global economies could have a significant adverse
impact on our investment income, the value of our investments, or future liquidity needs.
Because of the unknown pacing, intensity and duration of this pandemic, we cannot predict the impact of its
ultimate disruption to business activities, its employment and economic effects, its near and long-term impacts on
the patterns of care and services across the healthcare system, or the ultimate resulting impact on our business,
results of operations, financial position or cash flows.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates
periodically. There is no established expiration date for the program. During the first quarter 2020, we
repurchased approximately 6 million shares at an average price of $271.32 per share. As of March 31, 2020, we
had Board authorization to purchase up to 66 million shares of our common stock.
26

-- 30 of 36 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K.
The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to
Exhibit 3.1 to the Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Bylaws of UnitedHealth Group Incorporated, effective August 15, 2017 (incorporated by reference to
Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 16, 2017)
4.1 	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The
Bank of New York (incorporated by reference to Exhibit 4.1 to the Company’s Registration
Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2 	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998,
between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to
Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30,
2001)
4.3 	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant
to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among
UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company
(incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2007)
4.4 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank
National Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration
Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document—the instance document does not appear in the Interactive Data File
because its XBRL tags are embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain
holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
27

-- 31 of 36 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/ S/ 	DAVID S. W ICHMANN
David S. Wichmann
Chief Executive Officer
(principal executive officer)
Dated: May 6, 2020
/ S/ 	J OHN F. REX
John F. Rex
Executive Vice President and
Chief Financial Officer
(principal financial officer)
Dated: May 6, 2020
/ S/ 	THOMAS E. ROOS
Thomas E. Roos
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: May 6, 2020
28

-- 32 of 36 --

[THIS PAGE INTENTIONALLY LEFT BLANK]

-- 33 of 36 --

[THIS PAGE INTENTIONALLY LEFT BLANK]

-- 34 of 36 --



-- 35 of 36 --



-- 36 of 36 --